期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

甲状腺癌的分子标志物 被引量：4

Molecular markers for thyroid cancer
暂未订购
导出
摘要 甲状腺癌是常见的内分泌腺恶性肿瘤。灵敏度高、特异性强的肿瘤标志物有助于甲状腺癌的早期诊断,并为制定更合理的治疗方案提供帮助。近年来研究较多的肿瘤标志物主要有β-半乳糖结合蛋白、间皮细胞表面微绒毛抗原-1、三叶因子、细胞角蛋白、端粒酶反转录酶、血管内皮生长因子、降钙素、基质金属蛋白酶、组织蛋白酶及鼠类肉瘤滤过性毒菌致癌同源体B1、过氧化物酶增殖物激活受体、微小RNA以及转染重排/甲状腺乳头状癌等基因,其灵敏度及特异性对不同类型的甲状腺癌有所差别,可以作为细针穿刺细胞学的辅助手段。 Thyroid cancer is a common endocrine malignancy.Tumor markers with high sensitivity and strong specificity are helpful for thyroid cancer early diagnosis and therapy.Recently,many of tumor markers have been reported.It includes galectin-3,Hector battifora mesothelial antigen-1,trefoil factor-3,cytokeratin,human telomerase reverse transcriptase,vascular endothelial growth factor,matrix metalloproteinases,cathepsin,v-raf murine sarcoma viral oncogene homolog B1,peroxisome proliferator-activated receptor gamma,MicroRNA,and rearranged during transfection / papillary thyroid carcinoma.The sensitivity and specificity of these tumor markers are different in various types of thyroid carcinoma and could be used as an adjuvant to the fine needle aspiration cytology.
作者 孔艳华 任安
机构地区 安徽医科大学附属安徽省立医院内分泌科
出处 《国际病理科学与临床杂志》 CAS 2011年第4期338-343,共6页 Journal of International Pathology and Clinical Medicine
关键词 甲状腺癌 肿瘤标志物 基因诊断 thyroid cancer tumor marker gene diagnosis
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献49

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010,60 ( 5 ) : 277-300.
  • 2Cooper DS, Doherty GM, Haugen BR,et al. Revised American Thyroid Association Management Guidelines for Patients with Thy- roid Nodules and D]fferenfiated Thyroid Cancer [J]. Thyroid, 2009,19 ( 11 ) .1167-1214.
  • 3Saussez S, Glinoer D, Chantrain G, et al. Serum galecdn-1 and galectin-3 levels in benign and malignant nodular thyroid disease [J]. Thyroid, 2008,18(7) :705-712.
  • 4Bartolazzi A, Orlandi F, Saggiorato E, et al. Galectin-3--expression analysis in the surgical selection of follicular thyroid nodules with in- determinate fine-needle aspiration cytology: a prospective multicen- tre study[J]. Lancet Oncol,2008,9(6) :543-549.
  • 5Kim MJ, Kim HJ, Hong SJ, et al. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions [ J ]. Acta Cytol, 2006,50 ( 1 ) :28-34.
  • 6Ersoz S, Sert H, Yandi M, et al. The significance of galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. [J]. Pathol Oncol Res,2008,14(4) : 457-460.
  • 7Lin CI, Whang EE, Donner DB, et al. Galectin-3 targeted thera- py with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer [J]. Mol Cancer Res,2009,7 (10) : 1655-1662.
  • 8Ito Y, Yoshida H, Tomoda C, et al. HBME-1 expression in follicular tumor of the thyroid : an investigation of whether it can be used as a marker to diagnose follicular carcinoma[J]. Anticancer Res ,2005,25 (1A) : 179-182.
  • 9Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemi- cal markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining [J ]. Modem Pathol,2006,19 ( 12 ) : 1631-1637.
  • 10de Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness ofHBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy [ J ]. Histopathology,2005,47 (4) : 391-401.

二级参考文献33

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量：1380
  • 2王亚秋,华清泉.甲状腺乳头状癌中缺氧诱导因子-1α和血管内皮生长因子及血管内皮生长因子-C表达的临床意义[J].临床耳鼻咽喉头颈外科杂志,2007,21(5):204-206. 被引量：12
  • 3奥斯伯F 金斯顿RE.精编分子生物学实验指南[M].北京:科学出版社,1998.29-108.
  • 4KRISHNAN J, KIRKIN V, STEFFEN A, et al. Differential invivo and invitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumor and its relationship to lymphatic metastasis in immunocompetentrats[J]. Cancer Res, 2003, 63: 713--722.
  • 5NAKASHIMA T, KONDOH S, KITOH H, et al. Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymphodemetastasis[J]. Int J Mol Med, 2003,11 : 33 -- 39.
  • 6FELLMER P T, SATO K, TANAKA R, et al. Vascular endothelial growth factor C gene expression in papillary and follicular thyroid carcinomas[J]. Surgery,1999,126:1056--1061.
  • 7GERSHENWALD J E, FIDLER I J. Targeting lymphatic metastasis [J]. Science, 2002, 296:1811 -- 1812.
  • 8MANDRIOTA S J, JUSSILA L, JELTSCH M, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumor metastasis [J]. EMBO J,2001,20:672-682.
  • 9PAPOUTSI M, SIEMEISTER G, WEINDEL K, et al. Active interaction of human A375 melanoma cells with the lymphatics in vivo[J]. Histochem Cell Biol, 2000,114:373--385.
  • 10FUNAKI H, NISHIMURA G, HARADA S, et al. Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma[J]. Oncology,2003,64:416-422.

共引文献28

同被引文献79

  • 1关海霞,单忠艳,米小轶,王恩华,滕卫平.普遍食盐碘化前后甲状腺癌发病变化的11年病理资料分析[J].中国医科大学学报,2006,35(3):284-285. 被引量：106
  • 2汤钊猷.现代肿瘤学[M].3版.上海:复旦大学出版社,2011:890-931.
  • 3Caminha LS, Momesso DP, Vaisman F, et al. Long- term follow-up of patients with differentiated thyroid cancer who had negative 1311 whole-body scan at first evaluation after treatment[J]. C/in Nucl Med, 201 3, 38(10):765-769.
  • 4Strati A, Kasimir-Bauer S, Markou A, et al. Comparison of three molecular assays for the detection and molecular characterization ofcirculating tumor cells in breast cancer[J]. Breast CancerRes, 2013, 15(2):R20.
  • 5Nath S, Mukherjee P. MUCI: a multifaceted oncoprotein with a key role in cancer progression[J]. Trends Mol Med, 2014, 20(6):332-342.
  • 6Morari EC, Silva JR, Guilhen AC, et al. Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome[J]. Endocr Pathol, 201 O, 21 (4):242-249.
  • 7Konturek A, Barczynski M, Nowak W, et a/. Prognostic factors in differentiated thyroid cancer--a 20-year surgical outcome study[J]. Langenbecks Arch Surg, 2012, 397(5):809-815.
  • 8Nixon IJ, Ganly I, Palmer FL, et al. Disease-related death in patients who were considered free of macroscopic disease after initial treatment of well-differentiated thyroid carcinoma[J]. Thyroid, 2011,21(5):501-504.
  • 9Grogan RH, Kaplan SP, Cao H, et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up[J]. Surgery, 2013, 154(6):1436-1446.
  • 10Yin L, Kufe T, Avigan D, et al. Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death[J]. Blood, 2014, 123(19):2997-3006.

引证文献4

二级引证文献10

国际病理科学与临床杂志
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部